目的 观察布地奈德联合博利康尼雾化吸入对支气管哮喘急性发作期的临床疗效.方法 选取57例急性发作期支气管哮喘患者随机分为治疗组(30例)和对照组(27例).两组均给与常规抗感染、祛痰以及氨茶碱平喘治疗,治疗组在常规治疗的基础上给予普米克令舒4ml与博利康尼2ml联合雾化吸入治疗,2次/d.结果 两组患者在治疗前观察指标差异无统计学意义(P＞0.05),治疗后治疗组哮喘症状体征及肺功能指标明显改善(P＜0.05).结论 雾化吸入布地奈德和博利康尼起效快,有效改善患者的哮喘症状体征及肺功能指标.%Objective To observe the joint Bricanyl Budesonide inhalation on bronchial asthma at acute stage of clinical efficacy. Methods 57 patients with acute exacerbation of asthma were randomly divided into treatment group (30 cases) and control group (27 patients). Both groups were given conventional anti-inflammatory, expectorant, and aminophylline treatment of asthma, the treatment group given routine treatment with Bricanyl Respules 2ml 4ml combined aerosol inhalation, 2 times/day. Results There were observed differences in the indices before treatment had no significant (P > 0. 05 ) , the treatment group, symptoms and signs of asthma and lung function were significantly improved ( P < 0. 05 ). Conclusion Budesonide inhalation and Bricanyl rapid onset of asthma patients improve lung function and symptoms and signs.
展开▼
